Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pimavanserin for Agitation and Aggression in Alzheimer's Disease
NCT02992132Phase 2Terminated
- Sponsor
- Acadia Pharmaceuticals
- Start
- Nov 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of pimavanserin in Alzheimer's disease (AD) (3 arms), sponsored by Acadia Pharmaceuticals. Primary endpoint: Cohen-Mansfield Agitation Inventory at 12 weeks. Started Nov 2016; status: terminated.
02
Drugs
pimavanserin
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02992132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02992132.